Effect of traditional Chinese medicine Qiliqiangxin in patients With HFrEF treated with sacubitril/valsartan: the QUEST trial
Heart failure with reduced ejection fraction (HFrEF) remains a leading cause of cardiovascular morbidity and mortality globally, despite recent advances in therapy, and new treatments that have added benefit are still needed. Qiliqiangxin (QLQX), a Traditional Chinese Medicine (TCM) formulation, has demonstrated...